Cargando…
A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer
Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overal...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687003/ https://www.ncbi.nlm.nih.gov/pubmed/32967061 http://dx.doi.org/10.1111/jcmm.15762 |
_version_ | 1783613441798307840 |
---|---|
author | Liu, Zijian Mi, Mi Li, Xiaoqian Zheng, Xin Wu, Gang Zhang, Liling |
author_facet | Liu, Zijian Mi, Mi Li, Xiaoqian Zheng, Xin Wu, Gang Zhang, Liling |
author_sort | Liu, Zijian |
collection | PubMed |
description | Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overall survival rate for breast cancer patients. Two algorithms, Least Absolute Shrinkage and Selector Operation (LASSO) and Support Vector Machine‐Recursive Feature Elimination (SVM‐RFE), were used to select candidate lncRNAs. Univariate and multivariate Cox regression analyses were employed to construct a seven‐lncRNA signature for breast cancer. Stratified analysis revealed that the signature was significantly associated with multiple clinicopathological risk factors. For clinical use, we developed a nomogram model to predict overall survival and odds of death for breast cancer patients. Single‐sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithm and ESTIMATE method were employed to assess the relative immune cell infiltrations of each sample. Differentially infiltration of immune cells and diverse tumour mutation burden (TMB) scores might give rise to the efficacy of lncRNA signature for predicting the overall survival of patients. Correlation analysis implied that LINC01215 was associated with multiple immune‐related signalling pathways. A seven‐lncRNA prognostic signature is a reliable tool to predict the prognosis of breast cancer patients. |
format | Online Article Text |
id | pubmed-7687003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-76870032020-12-03 A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer Liu, Zijian Mi, Mi Li, Xiaoqian Zheng, Xin Wu, Gang Zhang, Liling J Cell Mol Med Original Articles Current studies have shown that long non‐coding RNAs (lncRNAs) may serve as prognostic biomarkers in multiple cancers. Therefore, we postulated that expression patterns of multiple lncRNAs combined into a single signature could improve clinicopathological risk stratification and prediction of overall survival rate for breast cancer patients. Two algorithms, Least Absolute Shrinkage and Selector Operation (LASSO) and Support Vector Machine‐Recursive Feature Elimination (SVM‐RFE), were used to select candidate lncRNAs. Univariate and multivariate Cox regression analyses were employed to construct a seven‐lncRNA signature for breast cancer. Stratified analysis revealed that the signature was significantly associated with multiple clinicopathological risk factors. For clinical use, we developed a nomogram model to predict overall survival and odds of death for breast cancer patients. Single‐sample gene set enrichment analysis (ssGSEA), CIBERSORT algorithm and ESTIMATE method were employed to assess the relative immune cell infiltrations of each sample. Differentially infiltration of immune cells and diverse tumour mutation burden (TMB) scores might give rise to the efficacy of lncRNA signature for predicting the overall survival of patients. Correlation analysis implied that LINC01215 was associated with multiple immune‐related signalling pathways. A seven‐lncRNA prognostic signature is a reliable tool to predict the prognosis of breast cancer patients. John Wiley and Sons Inc. 2020-09-23 2020-11 /pmc/articles/PMC7687003/ /pubmed/32967061 http://dx.doi.org/10.1111/jcmm.15762 Text en © 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Liu, Zijian Mi, Mi Li, Xiaoqian Zheng, Xin Wu, Gang Zhang, Liling A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title | A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title_full | A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title_fullStr | A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title_full_unstemmed | A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title_short | A lncRNA prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
title_sort | lncrna prognostic signature associated with immune infiltration and tumour mutation burden in breast cancer |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687003/ https://www.ncbi.nlm.nih.gov/pubmed/32967061 http://dx.doi.org/10.1111/jcmm.15762 |
work_keys_str_mv | AT liuzijian alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT mimi alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT lixiaoqian alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT zhengxin alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT wugang alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT zhangliling alncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT liuzijian lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT mimi lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT lixiaoqian lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT zhengxin lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT wugang lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer AT zhangliling lncrnaprognosticsignatureassociatedwithimmuneinfiltrationandtumourmutationburdeninbreastcancer |